# Xencor Inc. (XNCR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $26.61, market value $2.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Xencor Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 18.8×**. Each dollar of revenue is priced at 18.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.5%** (5-yr avg -7.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -205.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -73.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -14.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -24.3%**. Return on all capital, debt included, is -24.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -18.7%**. Each dollar of assets produces -18.7% of profit.

## Growth
- **Revenue growth (1 yr): 13.7%** (3-yr -8.6%/yr, 5-yr 0.5%/yr). Revenue grew 13.7% over the last year, against 0.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 65.4%**. Earnings per share rose 65.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.19**. Debt is 0.19 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Xencor Inc. holds more cash than debt.
- **Altman Z-score: 5.44**. A Z-score of 5.44 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Xencor Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Xencor Inc.; the consensus is strong_buy, with an average price target of $30.08 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 217.9%** (YTD 73.8%, 3-mo 126.1%). The shares are up 217.9% over twelve months including dividends.
- **From 52-week high: -13.1%** (222.5% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.29** (volatility 67%). Beta of 1.29 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XNCR · Page: https://foliofundamentals.com/stocks/xncr

Not investment advice.